(Q40476934)

20 September 2017

1 reference

title

Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism (English)

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

31 July 2024

author name string

S. J. Froelich-Ammon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7665550

31 July 2024

N. Osheroff

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7665550

31 July 2024

language of work or name

English

0 references

publication date

1 September 1995

1 reference

20 September 2017

15 September 1995

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7665550

full work available at URL

31 July 2024

http://www.jbc.org/content/270/37/21429.full.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7665550

https://api.elsevier.com/content/article/PII:S0021925818901882?httpAccept=text/xml

31 July 2024

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

https://api.elsevier.com/content/article/PII:S0021925818901882?httpAccept=text/plain

31 July 2024

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

https://syndication.highwire.org/content/doi/10.1074/jbc.270.37.21429

31 July 2024

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Journal of Biological Chemistry

31 July 2024

published in

1 reference

20 September 2017

volume

270

1 reference

20 September 2017

issue

37

1 reference

20 September 2017

page(s)

21429-21432

1 reference

20 September 2017

1

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Biochemical basis for the interactions of type I and type II topoisomerases with DNA.

31 July 2024

3

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

DNA gyrase: structure and function.

31 July 2024

4

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

The twisted 'life' of DNA in the cell: bacterial topoisomerases

31 July 2024

6

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Eukaryotic DNA topoisomerases I.

31 July 2024

7

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Role of nonhistone proteins in the chromosomal events of mitosis

31 July 2024

9

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Fluoroquinolone antimicrobial agents

31 July 2024

11

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

The molecular basis of quinolone action

31 July 2024

12

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs

31 July 2024

14

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

DNA topoisomerase I and II in cancer chemotherapy: update and perspectives

31 July 2024

15

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

The current status of camptothecin analogues as antitumor agents

31 July 2024

16

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

DNA topoisomerases: essential enzymes and lethal targets

31 July 2024

17

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Topoisomerase inhibitors. A review of their therapeutic potential in cancer

31 July 2024

19

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

The DNA binding, cleavage, and religation reactions of eukaryotic topoisomerases I and II.

31 July 2024

21

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

31 July 2024

DNA topoisomerases

22

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Catalytic function of DNA topoisomerase II.

31 July 2024

23

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Structure and function of type II DNA topoisomerases

31 July 2024

24

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication

31 July 2024

25

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Yeast DNA topoisomerase II is encoded by a single-copy, essential gene

31 July 2024

26

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Structure of the Drosophila DNA topoisomerase II gene. Nucleotide sequence and homology among topoisomerases II.

31 July 2024

27

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

31 July 2024

28

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents

31 July 2024

29

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Topoisomerase II enzymes and mutagenicity

31 July 2024

30

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

The structural basis of camptothecin interactions with human serum albumin: impact on drug stability

31 July 2024

31

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones

31 July 2024

32

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26

31 July 2024

33

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

31 July 2024

34

55

78

Brown

1995

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus

31 July 2024

36

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Escherichia coli Mutants Thermosensitive for Deoxyribonucleic Acid Gyrase Subunit A: Effects on Deoxyribonucleic Acid Replication, Transcription, and Bacteriophage Growth

31 July 2024

38

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Deletion and duplication sequences induced in CHO cells by teniposide (VM-26), a topoisomerase II targeting drug, can be explained by the processing of DNA nicks produced by the drug-topoisomerase interaction

31 July 2024

39

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

31 July 2024

40

49

5077

Hsiang

1989

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase

31 July 2024

41

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors

31 July 2024

42

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells

31 July 2024

43

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

31 July 2024

44

47

3973

Sullivan

1987

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

31 July 2024

45

49

6318

Bjornsti

1989

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

31 July 2024

46

52

525

Madden

1992

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

31 July 2024

47

52

4467

Nitiss

1992

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

31 July 2024

48

55

2299

Ishida

1995

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Topoisomerase II: A specific marker for cell proliferation

31 July 2024

49

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I.

31 July 2024

51

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives

31 July 2024

52

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events

31 July 2024

53

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy

31 July 2024

54

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.

31 July 2024

55

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp

31 July 2024

57

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Using yeast to study resistance to topoisomerase II-targeting drugs.

31 July 2024

58

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

DNA topoisomerase-targeting antitumor drugs can be studied in yeast

31 July 2024

59

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

31 July 2024

60

53

89

Nitiss

1993

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide.

31 July 2024

61

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex

31 July 2024

62

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Proceedings of the National Academy of Sciences of the United States of America

31 July 2024

63

author name string

Pommier

publication date

1995

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

DNA topoisomerase-trapping antitumour drugs

31 July 2024

64

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons

31 July 2024

66

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide

31 July 2024

67

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Drug resistance associated with altered DNA topoisomerase II.

31 July 2024

68

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Yeast Saccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin

31 July 2024

69

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex

31 July 2024

71

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Molecular Interactions of DNA-Topoisomerase I and II Inhibitor with DNA and Topoisomerases and in Ternary Complexes: Binding Modes and Biological Effects for Intoplicine Derivatives

31 July 2024

72

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex

31 July 2024

73

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli

31 July 2024

74

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors

31 July 2024

75

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.

31 July 2024

76

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes

31 July 2024

77

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions

31 July 2024

78

1 reference

https://api.crossref.org/works/10.1074/JBC.270.37.21429

31 July 2024

Identifiers

1 reference

20 September 2017

1 reference